Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | CALCRL | Q16602 | 16/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834474 | 0.85 | GABRP (0.61) | KCNH2CALCRLRAMP1 | |
| SCHEMBL3859605 | 0.85 | GABRP (0.61) | KCNH2CALCRLRAMP1 | |
| SCHEMBL8223082 | 0.80 | KCNH2 (0.73) | KCNH2CALCRLRAMP1 | |
| SCHEMBL3249926 | 0.77 | NR1I2 (0.74) | KCNH2NR1I2ADORA3OPRM1OPRK1 | |
| SCHEMBL7212286 | 0.77 | KCNH2 (0.64) | KCNH2CALCRLRAMP1 | |
| SCHEMBL14497508 | 0.76 | OPRK1 (0.72) | OPRK1 | |
| SCHEMBL7871697 | 0.75 | CYP3A4 (0.55) | KCNH2NR1I2ADORA3OPRM1OPRK1 | |
| SCHEMBL8846319 | 0.75 | KCNH2 (0.77) | KCNH2CALCRLRAMP1 | |
| SCHEMBL8462639 | 0.75 | KCNH2 (0.77) | KCNH2CALCRLRAMP1 | |
| SCHEMBL8463081 | 0.75 | KCNH2 (0.85) | KCNH2CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641781-B1 | Benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-1641781-B1 | Benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1856100-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| EP-1856100-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006078554-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060148790-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | KCNH2 117/4885CALCRL 1/4885RAMP1 114/4885 |
| US-20060148790-A1 | Benzodiazepine cgrp receptor antagonists | BDKRB1, CCKBR, BDKRB2 | KCNH2 105/4885CALCRL 14/4885RAMP1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.